Consolidated Statements of Shareholders' Equity - USD ($) shares in Millions, $ in Millions		Total	Total CVS Health Shareholders’ Equity	Common Shares	Treasury Shares		Common Stock and Capital Surplus	[2]	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Shares outstanding, beginning of year balance (in shares) at Dec. 31, 2021				1,744
Treasury shares outstanding, beginning of year balance (in shares) at Dec. 31, 2021	[1]				(422)
Beginning of year balance at Dec. 31, 2021		$ 74,841	$ 74,535		$ (28,173)	[1]	$ 47,377		$ 54,997	$ 334	$ 306
Stockholders' Equity [Roll Forward]
Net income		4,327	4,311						4,311		16
Other comprehensive income (loss)		(1,598)	(1,598)							(1,598)
Stock option activity, stock awards and other (in shares)				14
Stock option activity, stock awards and other		816	816				816
Purchase of treasury shares, net of ESPP issuances (in shares)	[1]				(36)
Purchase of treasury shares, net of ESPP issuances		(3,685)	(3,685)		$ (3,685)	[1]
Common stock dividends ($2.20 per share)		(2,910)	(2,910)						(2,910)
Other increases (decreases) in noncontrolling interests		(22)									(22)
Shares outstanding, end of year balance (in shares) at Dec. 31, 2022				1,758
Treasury shares outstanding, end of year balance (in shares) at Dec. 31, 2022	[1]				(458)
End of year balance at Dec. 31, 2022		71,769	71,469		$ (31,858)	[1]	48,193		56,398	(1,264)	300
Stockholders' Equity [Roll Forward]
Net income		8,368	8,344						8,344		24
Other comprehensive income (loss)		967	967							967
Stock option activity, stock awards and other (in shares)				10
Stock option activity, stock awards and other		795	795				795
Purchase of treasury shares, net of ESPP issuances (in shares)	[1]				(22)
Purchase of treasury shares, net of ESPP issuances		(1,992)	(1,992)		$ (1,980)	[1]	(12)
Common stock dividends ($2.20 per share)		(3,138)	(3,138)						(3,138)
Acquisition of noncontrolling interests		66									66
Other increases (decreases) in noncontrolling interests		$ (199)	16				16				(215)
Shares outstanding, end of year balance (in shares) at Dec. 31, 2023				1,768
Treasury shares outstanding, end of year balance (in shares) at Dec. 31, 2023		(480)			(480)	[1]
End of year balance at Dec. 31, 2023		$ 76,636	76,461		$ (33,838)	[1]	48,992		61,604	(297)	175
Stockholders' Equity [Roll Forward]
Net income		4,586	4,614						4,614		(28)
Other comprehensive income (loss)		177	177							177
Stock option activity, stock awards and other (in shares)				10
Stock option activity, stock awards and other		700	700				700
Purchase of treasury shares, net of ESPP issuances (in shares)	[1]				(38)
Purchase of treasury shares, net of ESPP issuances		(3,002)	(3,002)		$ (2,980)	[1]	(22)
Common stock dividends ($2.20 per share)		(3,381)	(3,381)						(3,381)
Other increases (decreases) in noncontrolling interests		$ 14	(9)				(9)				23
Shares outstanding, end of year balance (in shares) at Dec. 31, 2024				1,778
Treasury shares outstanding, end of year balance (in shares) at Dec. 31, 2024		(518)			(518)	[1]
End of year balance at Dec. 31, 2024		$ 75,730	$ 75,560		$ (36,818)	[1]	$ 49,661		$ 62,837	$ (120)	$ 170

[1] Treasury shares include 1 million shares held in trust for each of the years ended December 31, 2024, 2023 and 2022. Treasury stock includes $29 million related to shares held in trust for each of the years ended December 31, 2024, 2023 and 2022. See Note 1 ‘‘Significant Accounting Policies’’ for additional information.

[2] Common stock and capital surplus includes the par value of common stock of $18 million as of December 31, 2024, 2023 and 2022.